Cancer Research Cancer Epigenetics  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malathi, K.
Right arrow Articles by Silverman, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malathi, K.
Right arrow Articles by Silverman, R. H.
[Cancer Research 64, 9144-9151, December 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

HPC1/RNASEL Mediates Apoptosis of Prostate Cancer Cells Treated with 2',5'-Oligoadenylates, Topoisomerase I Inhibitors, and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Krishnamurthy Malathi1, Jayashree M. Paranjape1, Ram Ganapathi2 and Robert H. Silverman1

1 Department of Cancer Biology, Lerner Research Institute, and 2 Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio

The hereditary prostate cancer 1 (HPC1) allele maps to the RNASEL gene encoding a protein (RNase L) implicated in the antiviral activity of interferons. To investigate the possible role of RNase L in apoptosis of prostate cancer cells, we decreased levels of RNase L by severalfold in the DU145 human prostate cancer cell line through the stable expression of a small interfering RNA (siRNA). Control cells expressed siRNA with three mismatched nucleotides to the RNase L sequence. Cells deficient in RNase L, but not the control cells, were highly resistant to apoptosis by the RNase L activator, 2',5'-oligoadenylate (2-5A). Surprisingly, the RNase L-deficient cells were also highly resistant to apoptosis by combination treatments with a topoisomerase (Topo) I inhibitor (camptothecin, topotecan, or SN-38) and tumor necrosis factor-related apoptosis-inducing ligand [TRAIL (Apo2L)]. In contrast, cells expressing siRNA to the RNase L inhibitor RLI (HP68) showed enhanced apoptosis in response to Topo I inhibitor alone or in combination with TRAIL. An inhibitor of c-Jun NH2-terminal kinases reduced apoptosis induced by treatment with either 2-5A or the combination of camptothecin and TRAIL, thus implicating c-Jun NH2-terminal kinase in the apoptotic signaling pathway. Furthermore, prostate cancer cells were sensitive to apoptosis from the combination of 2-5A with either TRAIL or Topo I inhibitor, whereas normal prostate epithelial cells were partially resistant to apoptosis. These findings indicate that RNase L integrates and amplifies apoptotic signals generated during treatment of prostate cancer cells with 2-5A, Topo I inhibitors, and TRAIL.




This article has been cited by other articles:


Home page
J. Virol.Home page
R. H. Silverman
Viral Encounters with 2',5'-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response
J. Virol., December 1, 2007; 81(23): 12720 - 12729.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. S. Thakur, B. K. Jha, B. Dong, J. Das Gupta, K. M. Silverman, H. Mao, H. Sawai, A. O. Nakamura, A. K. Banerjee, A. Gudkov, et al.
Small-molecule activators of RNase L with broad-spectrum antiviral activity
PNAS, June 5, 2007; 104(23): 9585 - 9590.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Dong, S. Kim, S. Hong, J. Das Gupta, K. Malathi, E. A. Klein, D. Ganem, J. L. DeRisi, S. A. Chow, and R. H. Silverman
From the Cover: An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors
PNAS, January 30, 2007; 104(5): 1655 - 1660.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
R. J. Molinaro, B. K. Jha, K. Malathi, S. Varambally, A. M. Chinnaiyan, and R. H. Silverman
Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells
Nucleic Acids Res., December 2, 2006; 34(22): 6684 - 6695.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
X. M. Luo and A. C. Ross
Retinoic Acid Exerts Dual Regulatory Actions on the Expression and Nuclear Localization of Interferon Regulatory Factor-1.
Experimental Biology and Medicine, May 1, 2006; 231(5): 619 - 631.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Malathi, J. M. Paranjape, E. Bulanova, M. Shim, J. M. Guenther-Johnson, P. W. Faber, T. E. Eling, B. R. G. Williams, and R. H. Silverman
A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L
PNAS, October 11, 2005; 102(41): 14533 - 14538.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.